查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715329

心臟生物標記診斷試劑套件市場：按生物標記類型、適應症、檢測類型、購買類型、應用和最終用戶分類－2025-2030 年全球預測

Cardiac Biomarker Diagnostic Kits Market by Biomarker Type, Indication, Testing Type, Purchasing Mode, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

心臟生物標記診斷套件市場預計在 2024 年價值 32.2 億美元，2025 年價值 34.5 億美元，預計到 2030 年將達到 49 億美元，複合年成長率為 7.22%。

主要市場統計數據
基準年2024年 32.2億美元
預計2025年 34.5億美元
預測年份 2030 49億美元
複合年成長率（%） 7.22%

心臟生物標記診斷套件市場處於醫療創新的前沿，滿足了心血管評估和患者照護的關鍵需求。近年來，早期發現和早期療育的需求推動了診斷準確性的提高。由於心血管疾病仍然是世界各地導致死亡的主要原因之一，將先進的診斷試劑套件整合到臨床實踐中已經變得至關重要。

報告首先概述了市場格局，並強調了從傳統測試方法到尖端自動化平台的演變。分析表明，正在進行的研究、監管合作和技術突破不僅滿足了當前的醫療保健需求，而且還為未來的診斷趨勢設定了步伐。本書以資料主導的見解為基礎，強調了利用這些先進診斷工具的臨床和經濟效益。

透過探索市場促進因素、挑戰和新興機會，本介紹為深入討論轉型轉變、關鍵細分、區域發展、主要參與者、實用建議以及採取果斷行動的關鍵呼籲奠定了基礎。這裡彙編的見解旨在指南專家、臨床決策者和行業相關人員應對這個動態發展的市場。

重新定義診斷格局的轉折點

診斷領域經歷了一場變革性的轉變，重新定義了心臟疾病的檢測和治療方式。從歷史上看，依賴傳統的實驗室檢測方法限制了早期心血管干預所需的速度和準確性。然而，最近的技術進步正在推動診斷試劑套件向更快、更可靠和多功能的模式轉移。

先進的診斷成像技術與數位健康解決方案的融合在這一演變中發揮關鍵作用。現代診斷設備現在可以實現即時資料收集，有助於加快關鍵測試結果。自動化和複雜的生物檢測技術的整合正在簡化業務，從而減少人為錯誤並提高診斷結果的可重複性。

此外，監管機構也認知到這些創新的變革力量，為突破性診斷工具提供快速核准，並創造競爭性的研發環境。即時檢驗的引入進一步體現了這種轉變，確保可以直接在患者床邊進行高品質的診斷，而不僅僅是在專科實驗室進行。

在精準醫療快速崛起的時代，心臟生物標記診斷試劑套件的進步有助於制定個人化的治療方案。隨著臨床實驗室和醫院擴大採用這些技術，整個醫療保健生態系統將受益於患者治療效果的改善和診斷效率的提高。

影響市場動態的關鍵細分洞察

對市場細分的詳細分析揭示了關鍵見解，突顯了心臟生物標記診斷套件領域的多樣性和複雜性。當考慮生物標記的類型時，市場會針對 B 型利鈉肽、C 反應蛋白、心肌肌鈣蛋白、肌酸激酶-MB 和肌紅蛋白進行詳細分析。這些生物標記在診斷和監測心血管功能方面都發揮著獨特的作用，可提供廣泛的應用來滿足不同的臨床需求。

除了生物標記分類外，診斷試劑套件還將根據適應症進行評估，重點領域是心絞痛、心臟衰竭和心肌梗塞。這種分類不僅與常見的心臟疾病相吻合，而且還為這些套件在不同患者情況下的臨床部署提供了見解。此矩陣根據測試類型進一步細分，區分體外和體內測試環境。這種細分突顯了診斷解決方案對不同臨床環境和監管標準的適應性。

此外，採購模型透過將市場狀況分為直接採購和第三方供應商，反映了產業內的業務偏好和供應鏈動態，這對了解市場趨勢有很大幫助。應用評估著重於實驗室檢測和監測應用，前者進一步分為中央實驗室檢測和就地檢驗。這種複雜的細分凸顯了與更即時的床邊診斷需求相比，業務如何在集中環境中利用先進技術。

最後，基於最終用戶的細分包括學術和研究機構、診斷實驗室以及醫院和診所。對最終用戶資料的詳細剖析為目標市場提供了寶貴的見解，並有助於資源分配，以確保診斷套件符合不同操作環境的嚴格標準。總體而言，這種細分分析可作為將技術創新與實際市場需求相結合的藍圖，從而增強產品開發和策略市場開發。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球心血管疾病盛行率不斷上升
      • 醫療保健專業人員越來越意識到準確的心臟診斷方法的重要性
      • 不健康生活型態及相關風險因素激增
    • 限制因素
      • 與樣品採集和製備程序相關的複雜性
    • 機會
      • 利用巨量資料和預測分析來提高心臟診斷的準確性和效率
      • 生物標記檢測方法的技術進步
    • 任務
      • 心臟生物標記診斷套件的複雜監管核准流程
  • 市場區隔分析
    • 生物標記類型：B型利鈉肽在心臟衰竭診斷和監測中的重要性日益增強
    • 應用：擴大心臟生物標記診斷套件在實驗室檢測的應用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 心臟生物標記診斷試劑套件市場（依生物標記類型）

  • B型利鈉肽
  • C反應蛋白
  • 心臟肌鈣蛋白
  • 肌酸激酶MB
  • 肌紅蛋白

第7章心臟生物標記診斷試劑套件市場（按適應症）

  • 心絞痛
  • 心臟衰竭
  • 心肌梗塞

8. 心臟生物標記診斷試劑套件市場（依測試類型）

  • 體外測試
  • 體內測試

9. 心臟生物標記診斷試劑套件市場（按購買模式）

  • 直接購買
  • 第三方供應商

第 10 章：心臟生物標記診斷試劑套件市場（按應用）

  • 實驗室測試
    • 中央實驗室測試
    • 就地檢驗
  • 調查應用

第 11 章心臟生物標記診斷試劑套件市場（按最終用戶）

  • 學術研究所
  • 診斷實驗室
  • 醫院和診所

12.美洲心臟生物標記診斷試劑套件市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區心臟生物標記診斷試劑套件市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲心臟生物標記診斷套件市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • Atlas Medical GmbH
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • Eurolyser Diagnostica GmbH
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio Diagnostics, Inc.
  • GenWay Biotech, Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • J.Mitra & Co. Pvt. Ltd.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic Inc.
  • Meridian Bioscience, Inc.
  • MP Biomedicals, LLC
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthcare GmbH
  • Singulex, Inc.
  • SSI Diagnostica A/S Group
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Trivitron Healthcare
  • Tulip Diagnostics（P）Ltd
Product Code: MRR-433AB1DC288A

The Cardiac Biomarker Diagnostic Kits Market was valued at USD 3.22 billion in 2024 and is projected to grow to USD 3.45 billion in 2025, with a CAGR of 7.22%, reaching USD 4.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 3.22 billion
Estimated Year [2025] USD 3.45 billion
Forecast Year [2030] USD 4.90 billion
CAGR (%) 7.22%

The cardiac biomarker diagnostic kits market stands at the forefront of medical innovation, addressing critical needs in cardiovascular assessment and patient care. In recent years, the enhancement in diagnostic precision has been driven by the demand for early detection and intervention. As cardiovascular diseases continue to represent one of the leading causes of global mortality, the integration of advanced diagnostic kits into clinical practice has become indispensable.

This report initiates with an overview of the market environment, highlighting the evolution from traditional testing methods to state-of-the-art automated platforms. Analysis reveals that ongoing research, regulatory collaborations, and technological breakthroughs are not only meeting current healthcare demands but are also setting the pace for future diagnostic trends. The narrative is supported by data-driven insights that underscore the clinical and economic benefits of leveraging these advanced diagnostic tools.

Through an exploration of market drivers, challenges, and emergent opportunities, this introduction lays the foundation for a detailed discourse on the transformative shifts, key segmentation, regional developments, prominent players, practical recommendations, and a conclusive call for decisive action. The insights compiled herein are intended to guide professionals, clinical decision-makers, and industry stakeholders in navigating this dynamically evolving market.

Transformative Shifts Redefining the Diagnostic Landscape

The diagnostic landscape has witnessed transformative shifts that have redefined the manner in which cardiac conditions are detected and managed. Historically, the reliance on conventional laboratory testing methods limited the speed and accuracy required for early cardiovascular intervention. However, recent innovations have spurred a paradigm shift toward more rapid, reliable, and multifunctional diagnostic kits.

Advanced imaging techniques and the integration of digital health solutions have played a pivotal role in this evolution. Modern diagnostic instruments now facilitate real-time data collection that supports faster turnaround times for critical test results. The integration of automation and sophisticated bioassay technologies has streamlined operations, thereby reducing human error and enhancing the reproducibility of diagnostic outcomes.

Moreover, regulatory bodies have recognized the transformative power of these innovations, offering expedited pathways for the approval of breakthrough diagnostic tools and fostering an environment of competitive research and development. The introduction of point-of-care testing further exemplifies this shift, ensuring that high-quality diagnostics are available not only in specialized laboratories but also directly at the patient's bedside.

In an era where precision medicine is rapidly emerging, the advancements in cardiac biomarker diagnostic kits have become instrumental in tailoring individualized treatment plans. As clinical laboratories and hospitals increasingly adopt these technologies, the entire healthcare ecosystem is benefiting from improved patient outcomes and enhanced diagnostic efficiency.

Key Segmentation Insights Shaping Market Dynamics

An in-depth analysis of the market segmentation reveals significant insights that underscore the diversity and complexity of the cardiac biomarker diagnostic kits sector. When considering biomarker type, the market is meticulously analyzed across B-Type Natriuretic Peptide, C-Reactive Protein, Cardiac Troponin, Creatine Kinase-MB, and Myoglobin. Each of these biomarkers plays a distinct role in diagnosing and monitoring cardiovascular functions, thereby offering a broad spectrum of applications that address varied clinical needs.

In addition to biomarker classification, the diagnostic kits are evaluated based on the indication, with key focus areas spanning Angina Pectoris, Heart Failure, and Myocardial Infarction. This categorization not only aligns with prevalent cardiac conditions but also offers insights into the clinical deployment of these kits in different patient scenarios. The matrix is further segmented by testing type, differentiating between In Vitro Testing and In Vivo Testing environments. Such segmentation highlights the adaptability of diagnostic solutions to different clinical settings and regulatory standards.

Furthermore, purchasing mode contributes significantly to understanding market behavior, as it categorizes the landscape into Direct Purchasing and Third-Party Suppliers, thereby reflecting the operational preferences and supply chain dynamics within the industry. When evaluating applications, the primary emphasis is on Laboratory Testing and Research Applications; the former is further dissected into Central Laboratory Testing and Point-of-Care Testing. This intricate breakdown underscores how operational implementers leverage advanced technology in centralized settings compared to more immediate, bedside diagnostic needs.

Finally, the segmentation based on end users encompasses Academic & Research Institutions, Diagnostic Laboratories, and Hospitals & Clinics. This detailed dissection of the end user profile provides valuable insights into target markets and helps in the allocation of resources to ensure that the diagnostic kits meet the rigorous standards of diverse operational environments. Overall, this segmentation analysis serves as a roadmap for aligning technological innovations with practical market requisites, thereby enhancing both product development and strategic market positioning.

Based on Biomarker Type, market is studied across B-Type Natriuretic Peptide, C-Reactive Protein, Cardiac Troponin, Creatine Kinase-MB, and Myoglobin.

Based on Indication, market is studied across Angina Pectoris, Heart Failure, and Myocardial Infarction.

Based on Testing Type, market is studied across In Vitro Testing and In Vivo Testing.

Based on Purchasing Mode, market is studied across Direct Purchasing and Third-Party Suppliers.

Based on Application, market is studied across Laboratory Testing and Research Applications. The Laboratory Testing is further studied across Central Laboratory Testing and Point-of-Care Testing.

Based on End User, market is studied across Academic & Research Institutions, Diagnostic Laboratories, and Hospitals & Clinics.

Key Regional Insights Influencing Market Growth

On a geographic scale, the cardiac biomarker diagnostic kits market exhibits nuanced trends across distinct regions, each contributing uniquely to overall market growth. In the Americas, a robust healthcare infrastructure combined with increasing investments in advanced medical diagnostics is catalyzing widespread adoption. The region's emphasis on preventive healthcare and chronic disease management has significantly boosted the demand for rapid and reliable diagnostic solutions.

In the Europe, Middle East & Africa region, a blend of stringent regulatory frameworks and a growing emphasis on personalized medicine is creating a conducive environment for the deployment of innovative diagnostic kits. The collaborative initiatives between public health institutions and private players are leading to enhanced technology transfer and market penetration.

Meanwhile, the Asia-Pacific region is emerging as a critical hub, driven by economic growth, rising awareness about cardiovascular health, and significant government support for healthcare innovation. The dynamic nature of this market showcases an increasing appetite for advanced diagnostics in both urban centers and remote locations, thereby fostering a more inclusive and comprehensive healthcare approach.

Taken together, these regional insights illustrate how local market conditions, regulatory landscapes, and socio-economic factors collaboratively shape the global outlook of the cardiac biomarker diagnostic kits sector.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Shaping Industry Leadership

The industry is characterized by the strategic maneuvers and pioneering efforts of several leading companies, who continue to drive innovation and competitive differentiation within the cardiac biomarker diagnostic kits market. Global giants such as Abbott Laboratories, Beckman Coulter, Inc., and Bio-Rad Laboratories, Inc. remain at the forefront by consistently enhancing their product portfolios. They have set high benchmarks in terms of accuracy, speed, and clinical relevance, ensuring their methodologies resonate with the evolving requirements of healthcare providers.

In parallel, companies like Atlas Medical GmbH, bioMerieux SA, and Creative Diagnostics are leveraging niche expertise to address specialized diagnostic challenges. Other prominent players, including Eurolyser Diagnostica GmbH and F. Hoffmann-La Roche Ltd., have integrated advanced automation and data analytics into their workflows, reshaping the landscape for rapid diagnostics.

Fujirebio Diagnostics, Inc., GenWay Biotech, Inc., and Guangzhou Wondfo Biotech Co., Ltd. have further contributed to the market by introducing innovative platforms that merge clinical-grade performance with cost-efficiency. J.Mitra & Co. Pvt. Ltd. and Lepu Medical Technology (Beijing) Co., Ltd. are renowned for their commitment to developing robust diagnostic tools adaptable across varied healthcare settings.

Additionally, Medtronic Inc. and Meridian Bioscience, Inc. have expanded their global presence by tapping into regulatory advancements and market-specific trends. MP Biomedicals, LLC, Radiometer Medical ApS, and Randox Laboratories Ltd. continue to invest significantly in research and development, ensuring their offerings are both cutting-edge and clinically relevant. Siemens Healthcare GmbH, Singulex, Inc., SSI Diagnostica A/S Group, Thermo Fisher Scientific, Inc., Tosoh Corporation, Trivitron Healthcare, and Tulip Diagnostics (P) Ltd. further enrich the competitive fabric of the market through strategic partnerships and continuous innovation.

Collectively, these companies form a competitive mosaic where excellence is driven by customization, technological integration, and a firm commitment to quality, all aimed at elevating standards of patient care across a broad spectrum of clinical settings.

The report delves into recent significant developments in the Cardiac Biomarker Diagnostic Kits Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Atlas Medical GmbH, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Creative Diagnostics, Eurolyser Diagnostica GmbH, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, Inc., GenWay Biotech, Inc., Guangzhou Wondfo Biotech Co., Ltd., J.Mitra & Co. Pvt. Ltd., Lepu Medical Technology (Beijing) Co., Ltd., Medtronic Inc., Meridian Bioscience, Inc., MP Biomedicals, LLC, Radiometer Medical ApS, Randox Laboratories Ltd., Siemens Healthcare GmbH, Singulex, Inc., SSI Diagnostica A/S Group, Thermo Fisher Scientific, Inc., Tosoh Corporation, Trivitron Healthcare, and Tulip Diagnostics (P) Ltd. Actionable Recommendations for Forward-Thinking Industry Leaders

Industry leaders seeking to excel in the cardiac biomarker diagnostic kits segment must align strategic investments with future market trends. It is essential to harness the power of data analytics and artificial intelligence, integrating real-time diagnostic data with predictive modeling to enhance decision-making and patient outcomes. Emphasizing research collaborations with academic and clinical institutions can drive the development of next-generation biomarker assays, ultimately expanding the scope and accuracy of diagnostic solutions.

Leaders should also focus on adopting an agile supply chain model, one that leverages both direct purchasing and strategic alliances with third-party suppliers, ensuring that the latest diagnostic innovations are seamlessly integrated into healthcare systems. Exploring diversified testing modalities by streamlining the offerings between central laboratory testing and point-of-care environments will not only broaden market penetration but also cater to the diverse needs of clinical settings.

Investing in training and ongoing education for healthcare professionals is critical for maximizing the potential of advanced diagnostic tools. This, in turn, reinforces the quality of patient care while simultaneously driving market adoption. Embracing regulatory compliance and ensuring alignment with emerging global standards is equally vital, as it bolsters trust and facilitates smoother market entry.

By maintaining a proactive stance in technology adoption, research partnerships, and process optimization, industry leaders can build resilient business models that not only respond to current market dynamics but also anticipate future shifts. This holistic approach ensures sustainable competitive advantages and positions organizations at the forefront of diagnostic innovation.

Conclusion: Charting a Course for a Diagnostic Revolution

As the cardiac biomarker diagnostic kits market continues to expand, the confluence of technological innovations, strategic market segmentation, and evolving regional dynamics paints a promising picture for the future. The detailed examination of biomarker types, clinical indications, testing modalities, purchasing preferences, and end-user dynamics reveals a complex yet highly adaptable market ecosystem.

The competitive landscape, bolstered by both established industry giants and innovative newcomers, underscores a collective drive towards precision, reliability, and enhanced patient care. As this market evolves, the integration of advanced diagnostics into routine clinical practice will become even more critical, paving the way for faster clinical interventions and improved health outcomes.

In summation, the insights provided in this review serve as a vital tool for stakeholders aiming to navigate the intricacies of the evolving diagnostic landscape, fostering a culture of continuous improvement and strategic foresight.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cardiovascular diseases globally
      • 5.1.1.2. Growing awareness among healthcare professionals about the importance of accurate cardiac diagnosis methods
      • 5.1.1.3. Surge in unhealthy lifestyles and related risk factors
    • 5.1.2. Restraints
      • 5.1.2.1. Complexities associated with sample collection and preparation procedures
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging big data for predictive analytics to enhance cardiac diagnostic precision and efficiency
      • 5.1.3.2. Technological advancements in biomarker detection methods
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory approval process for cardiac biomarker diagnostic kits
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Rising significance of B-type natriuretic peptide for diagnosing and monitoring heart failure
    • 5.2.2. Application: Expanding application of cardiac biomarker diagnostic kits in laboratory testing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cardiac Biomarker Diagnostic Kits Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. B-Type Natriuretic Peptide
  • 6.3. C-Reactive Protein
  • 6.4. Cardiac Troponin
  • 6.5. Creatine Kinase-MB
  • 6.6. Myoglobin

7. Cardiac Biomarker Diagnostic Kits Market, by Indication

  • 7.1. Introduction
  • 7.2. Angina Pectoris
  • 7.3. Heart Failure
  • 7.4. Myocardial Infarction

8. Cardiac Biomarker Diagnostic Kits Market, by Testing Type

  • 8.1. Introduction
  • 8.2. In Vitro Testing
  • 8.3. In Vivo Testing

9. Cardiac Biomarker Diagnostic Kits Market, by Purchasing Mode

  • 9.1. Introduction
  • 9.2. Direct Purchasing
  • 9.3. Third-Party Suppliers

10. Cardiac Biomarker Diagnostic Kits Market, by Application

  • 10.1. Introduction
  • 10.2. Laboratory Testing
    • 10.2.1. Central Laboratory Testing
    • 10.2.2. Point-of-Care Testing
  • 10.3. Research Applications

11. Cardiac Biomarker Diagnostic Kits Market, by End User

  • 11.1. Introduction
  • 11.2. Academic & Research Institutions
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals & Clinics

12. Americas Cardiac Biomarker Diagnostic Kits Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Cardiac Biomarker Diagnostic Kits Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Cardiac Biomarker Diagnostic Kits Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Siemens Atellica IM TnIH test gets FDA approval to predict cardiac events
    • 15.3.2. Cardio Diagnostics Holdings Inc. launched a redesigned website, CDIO.AI to enhance cardiovascular solutions
    • 15.3.3. Siemens Healthineers enhanced its Atellica cardiac testing menu with the NT-proBNPII assay
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Atlas Medical GmbH
  • 3. Beckman Coulter, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Creative Diagnostics
  • 7. Eurolyser Diagnostica GmbH
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Fujirebio Diagnostics, Inc.
  • 10. GenWay Biotech, Inc.
  • 11. Guangzhou Wondfo Biotech Co., Ltd.
  • 12. J.Mitra & Co. Pvt. Ltd.
  • 13. Lepu Medical Technology (Beijing) Co., Ltd.
  • 14. Medtronic Inc.
  • 15. Meridian Bioscience, Inc.
  • 16. MP Biomedicals, LLC
  • 17. Radiometer Medical ApS
  • 18. Randox Laboratories Ltd.
  • 19. Siemens Healthcare GmbH
  • 20. Singulex, Inc.
  • 21. SSI Diagnostica A/S Group
  • 22. Thermo Fisher Scientific, Inc.
  • 23. Tosoh Corporation
  • 24. Trivitron Healthcare
  • 25. Tulip Diagnostics (P) Ltd

LIST OF FIGURES

  • FIGURE 1. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET MULTI-CURRENCY
  • FIGURE 2. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET MULTI-LANGUAGE
  • FIGURE 3. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET RESEARCH PROCESS
  • FIGURE 4. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET DYNAMICS
  • TABLE 7. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY C-REACTIVE PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CARDIAC TROPONIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CREATINE KINASE-MB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ANGINA PECTORIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY IN VITRO TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY IN VIVO TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIRECT PURCHASING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY THIRD-PARTY SUPPLIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY CENTRAL LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 177. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 191. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 268. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 275. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 289. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 296. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 298. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY PURCHASING MODE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND CARDIAC BIOMARKER DIAGNOSTIC KITS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND